Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
24 February 2017 - 11:30PM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that the Company will
hold its Annual General Meeting (AGM) of Shareholders
on Thursday, May 11, 2017 at the offices of Arthur
Cox, Earlsfort Terrace, Dublin, Ireland. The
Company will announce the time of the AGM at a later date.
The record date for shareholders entitled to receive notice of and
vote at the AGM is Wednesday, March 22, 2017.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs. Strongbridge's first commercial product is KEVEYIS®
(dichlorphenamide), the first and only FDA-approved treatment for
hyperkalemic, hypokalemic, and related variants of Primary Periodic
Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S.
through August 7, 2022. In addition to establishing this
neuromuscular disease franchise, the Company has a clinical-stage
pipeline of therapies for rare endocrine diseases. Strongbridge's
lead compounds include COR-003 (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and COR-005, a next-generation
somatostatin analog (SSA) being investigated for the treatment of
acromegaly, with potential additional applications in Cushing's
syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have
received orphan designation from the U.S. Food and Drug
Administration and the European Medicines Agency. For more
information, visit www.strongbridgebio.com.
Contacts
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2024 to May 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Strongbridge Biopharma PLC (NASDAQ): 0 recent articles
More News Articles